# Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

> **NCT05607953** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **TriSalus Life Sciences, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** SD-101
- **BIOLOGICAL:** anti-PD-1

## Key facts

- **NCT ID:** NCT05607953
- **Lead sponsor:** TriSalus Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2027-09
- **Final completion:** 2027-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607953, "Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05607953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*